Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies-Reference-Cited by-同舟云学术

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

Published:2023-03 Issue:3 Volume:91 Page:281-290
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Shafer Danielle,Kagan Amanda B.,Rudek Michelle A.,Kmieciak Maciej,Tombes Mary Beth,Shrader Ellen,Bandyopadhyay Dipankar,Hudson Daniel,Sankala Heidi,Weir Caryn,Lancet Jeffrey E.,Grant Steven^ORCID

Funder

National Institutes of Health

National Institutes of Health Experimental Therapeutics Clinical Trials Network

National Institutes of Health Clinical Pharmacology Training Grant

National Center for Advancing Translational Sciences

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-023-04511-0.pdf

Reference32 articles.

1. Do K, Doroshow JH, Kummar S (2013) Wee1 kinase as a target for cancer therapy. Cell Cycle 12(19):3159–3164

2. Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D et al (2012) Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26(6):1266–1276

3. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059–2074

4. Seedhouse C, Grundy M, Shang S, Ronan J, Pimblett H, Russell N et al (2009) Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine. Clin Cancer Res 15(23):7291–7298

5. Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM et al (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55(10):2301–2304

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells;Biomedicine & Pharmacotherapy;2024-08

2. Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial;Nature Medicine;2024-06-01

3. Application of Histone Deacetylase Inhibitor in Acute Myeloid Leukemia;PROG BIOCHEM BIOPHYS;2024

4. DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies;Blood;2024-05-23

5. RNA expression changes driven by altered epigenetics status related to NASH etiology;Biomedicine & Pharmacotherapy;2024-05